These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

991 related articles for article (PubMed ID: 33981518)

  • 1. Clinical Impact of the Early Use of Monoclonal Antibody LY-CoV555 (Bamlanivimab) on Mortality and Hospitalization Among Elderly Nursing Home Patients: A Multicenter Retrospective Study.
    Alam MM; Mahmud S; Aggarwal S; Fathma S; Al Mahi N; Shibli MS; Haque SM; Mahmud S; Ahmed Z
    Cureus; 2021 May; 13(5):e14933. PubMed ID: 33981518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of SARS CoV2-Neutralizing Monoclonal Antibody on Hospitalization and Mortality in Long-Term Care Facility Residents.
    Murillo M; Lomiguen C; Terrell M; King A; Lin J; Ferretti S
    Aging Dis; 2022 Oct; 13(5):1523-1531. PubMed ID: 36186125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.
    Chen P; Nirula A; Heller B; Gottlieb RL; Boscia J; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Adams AC; Van Naarden J; Custer KL; Shen L; Durante M; Oakley G; Schade AE; Sabo J; Patel DR; Klekotka P; Skovronsky DM;
    N Engl J Med; 2021 Jan; 384(3):229-237. PubMed ID: 33113295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.
    ; Lundgren JD; Grund B; Barkauskas CE; Holland TL; Gottlieb RL; Sandkovsky U; Brown SM; Knowlton KU; Self WH; Files DC; Jain MK; Benfield T; Bowdish ME; Leshnower BG; Baker JV; Jensen JU; Gardner EM; Ginde AA; Harris ES; Johansen IS; Markowitz N; Matthay MA; Østergaard L; Chang CC; Davey VJ; Goodman A; Higgs ES; Murray DD; Murray TA; Paredes R; Parmar MKB; Phillips AN; Reilly C; Sharma S; Dewar RL; Teitelbaum M; Wentworth D; Cao H; Klekotka P; Babiker AG; Gelijns AC; Kan VL; Polizzotto MN; Thompson BT; Lane HC; Neaton JD
    N Engl J Med; 2021 Mar; 384(10):905-914. PubMed ID: 33356051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bamlanivimab use in mild-to-moderate COVID-19 disease: A matched cohort design.
    Destache CJ; Aurit SJ; Schmidt D; Peet Erkes L; Tierney M; Vivekanandan R
    Pharmacotherapy; 2021 Sep; 41(9):743-747. PubMed ID: 34328670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comparison of SARS-COV-2 Neutralizing Antibody Therapies in High-Risk Patients with Mild to Moderate COVID-19 Disease at a Single Academic Hospital.
    Farcy DA; Dalley MT; Miro G; Swalley P; Sherman D; Nash J; Jodoin K; Cubeddu LX; Zitek T; Goldszer R
    J Emerg Med; 2022 Jan; 62(1):83-91. PubMed ID: 34489146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
    Gottlieb RL; Nirula A; Chen P; Boscia J; Heller B; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Klekotka P; Shen L; Skovronsky DM
    JAMA; 2021 Feb; 325(7):632-644. PubMed ID: 33475701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial.
    Cohen MS; Nirula A; Mulligan MJ; Novak RM; Marovich M; Yen C; Stemer A; Mayer SM; Wohl D; Brengle B; Montague BT; Frank I; McCulloh RJ; Fichtenbaum CJ; Lipson B; Gabra N; Ramirez JA; Thai C; Chege W; Gomez Lorenzo MM; Sista N; Farrior J; Clement ME; Brown ER; Custer KL; Van Naarden J; Adams AC; Schade AE; Dabora MC; Knorr J; Price KL; Sabo J; Tuttle JL; Klekotka P; Shen L; Skovronsky DM;
    JAMA; 2021 Jul; 326(1):46-55. PubMed ID: 34081073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016.
    Starr TN; Greaney AJ; Dingens AS; Bloom JD
    Cell Rep Med; 2021 Apr; 2(4):100255. PubMed ID: 33842902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bamlanivimab Reduces ED Returns and Hospitalizations and May Reduce COVID-19 Burden on Low-resource Border Hospitals.
    Quenzer FC; Lafree AT; Grey L; Singh S; Smyers C; Balog B; Guedez HM; McIntyre K; Wulfovich S; Ramirez J; Saikhon T; Tomaszewski C
    West J Emerg Med; 2022 Mar; 23(3):302-311. PubMed ID: 35679495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
    Kreuzberger N; Hirsch C; Chai KL; Tomlinson E; Khosravi Z; Popp M; Neidhardt M; Piechotta V; Salomon S; Valk SJ; Monsef I; Schmaderer C; Wood EM; So-Osman C; Roberts DJ; McQuilten Z; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013825. PubMed ID: 34473343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Experience of Bamlanivimab for Coronavirus Disease 2019 (COVID-19): A Case-Control Study.
    Kumar RN; Wu EL; Stosor V; Moore WJ; Achenbach C; Ison MG; Angarone MP
    Clin Infect Dis; 2022 Jan; 74(1):24-31. PubMed ID: 33846730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.
    Hirsch C; Park YS; Piechotta V; Chai KL; Estcourt LJ; Monsef I; Salomon S; Wood EM; So-Osman C; McQuilten Z; Spinner CD; Malin JJ; Stegemann M; Skoetz N; Kreuzberger N
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD014945. PubMed ID: 35713300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    Bariola JR; McCreary EK; Wadas RJ; Kip KE; Marroquin OC; Minnier T; Koscumb S; Collins K; Schmidhofer M; Shovel JA; Wisniewski MK; Sullivan C; Yealy DM; Nace DA; Huang DT; Haidar G; Khadem T; Linstrum K; Seymour CW; Montgomery SK; Angus DC; Snyder GM
    Open Forum Infect Dis; 2021 Jul; 8(7):ofab254. PubMed ID: 34250192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bamlanivimab Use in a Military Treatment Facility.
    Karr E; Chung T; Burtson K; Markert R; Kelly D
    Mil Med; 2022 Oct; 187(11-12):e1261-e1264. PubMed ID: 33993281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Outcomes of Early Treatment With Doxycycline for 89 High-Risk COVID-19 Patients in Long-Term Care Facilities in New York.
    Alam MM; Mahmud S; Rahman MM; Simpson J; Aggarwal S; Ahmed Z
    Cureus; 2020 Aug; 12(8):e9658. PubMed ID: 32802622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19.
    Jabr R; Khatri A; Anderson AD; Garcia LC; Viotti JB; Natori Y; Raja M; Camargo JF; Morris MI
    Transpl Infect Dis; 2023 Feb; 25(1):e14006. PubMed ID: 36704987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016.
    Starr TN; Greaney AJ; Dingens AS; Bloom JD
    bioRxiv; 2021 Feb; ():. PubMed ID: 33655250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.
    Dougan M; Nirula A; Azizad M; Mocherla B; Gottlieb RL; Chen P; Hebert C; Perry R; Boscia J; Heller B; Morris J; Crystal C; Igbinadolor A; Huhn G; Cardona J; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Dabora MC; Klekotka P; Shen L; Skovronsky DM;
    N Engl J Med; 2021 Oct; 385(15):1382-1392. PubMed ID: 34260849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing Monoclonal Antibody Use and COVID-19 Infection Outcomes.
    Ambrose N; Amin A; Anderson B; Barrera-Oro J; Bertagnolli M; Campion F; Chow D; Danan R; D'Arinzo L; Drews A; Erlandson K; Fitzgerald K; Garcia M; Gaspar FW; Gong C; Hanna G; Jones S; Lopansri B; Musser J; O'Horo J; Piantadosi S; Pritt B; Razonable RR; Roberts S; Sandmeyer S; Stein D; Vahidy F; Webb B; Yttri J
    JAMA Netw Open; 2023 Apr; 6(4):e239694. PubMed ID: 37093599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.